The EP4 antagonist vorbipiprant and an anti-PD-1 in MSS mCRC
RNA-seq (gene expression) · human · 23 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 23 samples: 23 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa TrialClinical cancer research : an official journal of the American Association for Cancer Research · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE281374_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1183748 and SRA study SRP544011. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 23 sample titles: 23 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8619438 Ro204 ileum FFPE slice
- GSM8619439 Ro363 ileum-colon FFPE slice
- GSM8619440 Ro366 lung FFPE slice
- GSM8619441 Ro392 rectum FFPE slice
- GSM8619442 Ro406 lung FFPE slice
- GSM8619443 Ro473 lung FFPE slice
- GSM8619444 Ro487 colon, FFPE slice
- GSM8619445 Ro511 ovary, FFPE slice
- GSM8619446 Ro520 lung, FFPE slice
- GSM8619447 Ro540 colon, FFPE slice
- GSM8619448 Ro583 colon-rectum, FFPE slice
- GSM8619449 Ro695 liver, FFPE slice
- GSM8619450 Ro753 liver, FFPE slice
- GSM8619451 Ro774 uterine cervix, FFPE slice
- GSM8619452 Ro798 colon, FFPE slice
- GSM8619453 Ro805 liver FFPE slice
- GSM8619454 Ro813 lung FFPE slice
- GSM8619455 Ro859 colon FFPE slice
- GSM8619456 Ro901 sigma, FFPE slice
- GSM8619457 Ro954 ileum, FFPE slice
- GSM8619458 Ro961 ileum-colon, FFPE slice
- GSM8619459 Ro970 sigma-rectum FFPE slice
- GSM8619460 Ro998 lung FFPE slice
- GSE299214 Orphan drug nitisinone combined with sorafenib synergistically boosts anti-PD-1 efficacy in MSS Colorectal Cancer [RNA-Seq] 6 samples shares anti-pd-1, mss
- GSE260598 Anti-tumor activity of a novelLAIR1antagonist in combination with anti-PD-1to treat collagen-rich solid tumors (GeoMx) 48 samples shares anti-pd-1, antagonist
- GSE260597 Anti-tumor activity of a novelLAIR1antagonist in combination with anti-PD-1to treat collagen-rich solid tumors (human) 6 samples shares anti-pd-1, antagonist
- GSE289582 Baseline tumor features and peripheral blood immune dynamics that underlie efficacy in MSS metastatic colorectal cancer treated with regorafenib, ipilimumab, and nivolumab [Blood] 115 samples shares mss
- GSE289743 Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy [RNA-Seq FFPE] 83 samples shares anti-pd-1
- GSE202069 RNA-seq data for tumor and adjacent non-tumor tissues from hepatocellular carcinoma patients with anti-PD-1 therapy 66 samples shares anti-pd-1
- GSE303456 Sequential Imatinib and Anti-PD-1 Therapy in KIT-Altered Melanoma: Mechanistic Insights and Clinical Benefit 48 samples shares anti-pd-1
- GSE179994 Temporal single cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer 47 samples shares anti-pd-1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.